CYP19A1 and breast carcinoma: ER/PR-positive breast cancers can be treated by hormonal therapies such as tamoxifen or aromatase inhibitors, while HER2-positive breast cancers respond well to targeted therapies like trastuzumab (Herceptin) [5].